Medication info
Lodivika Tablet 5/40 mg (Isamlodipine Nicotinate, Olmesartan Medoxomil)

Lodivika Tablet 5/40 mg (Isamlodipine Nicotinate, Olmesartan Medoxomil)

Prescription medicationTabletOral
Ingredient · strength
S-Amlodipine Nicotinate›6.506mg / 1 tabletOlmesartan Medoxomil›40mg / 1 tablet
Manufacturer / importer
Hanlim Pharmaceutical Co., Ltd.
Appearance
Reddish-brown round film-coated tablet
Packaging
30 tablets/bottle, 300 tablets/bottle
Approval status
Active

MFDS item code 201404533 · Approved 2014.09.30 · Insurance code 645305000

Summary

Main use
Treatment of essential hypertension not controlled with monotherapy
Who takes it
Adults · Children
Adult dose
This medicine should be taken once daily as 1 tablet with water, regardless of meals. If possible, it is recommended that it be taken at the same time each day (e.g., in the morning). Before starting this medicine, it is recommended that the dose be adjusted using the individual components (S-amlodipine (amlodipine) or olmesartan medoxomil). However, if blood pressure is not controlled with monotherapy using either individual component, switching directly to this medicine may be considered. The maximum dose of this medicine is 5/40 mg. The maximum blood pressure-lowering effect occurs within 2 weeks after administration; therefore, adjust the dose at intervals of at least 2 weeks, taking the patient's blood pressure response into consideration. The recommended doses are as follows. - 2.5/20 mg: For patients whose blood pressure is not adequately controlled with S-amlodipine 2.5 mg (amlodipine 5 mg) or olmesartan medoxomil 20 mg monotherapy. - 5/20 mg: For patients whose blood pressure is not adequately controlled with olmesartan medoxomil 20 mg monotherapy. - 2.5/40 mg: For patients whose blood pressure is not adequately controlled with 2.5/20 mg. - 5/40 mg: For patients whose blood pressure is not adequately controlled with 2.5/40 mg. ○ Patients with renal impairment: This medicine has not been studied in patients with renal impairment. However, the maximum dose of olmesartan medoxomil for patients with mild to moderate renal impairment (creatine clearance 20-60mL/min) is 20 mg once daily, and use of this medicine is not recommended in patients with moderate to severe renal impairment (e.g., creatinine clearance < 20 mL/min) or in patients on dialysis. Monitoring of potassium and creatinine levels is recommended in patients with moderate renal impairment. ○ Patients with reduced effective circulating blood volume: In patients who may have reduced effective circulating blood volume (Intravascular volume depletion) (e.g., patients receiving diuretics, especially those with renal impairment), it is recommended that treatment be initiated at a low dose with careful monitoring of their condition. ○ Patients with hepatic impairment: Use with caution in patients with mild to moderate hepatic impairment. The recommended initial dose of olmesartan medoxomil for patients with moderate hepatic impairment is 10 mg once daily, and the maximum dose is 20 mg once daily. Patients with hepatic impairment who are already receiving other antihypertensive agents and/or diuretics should be closely monitored for blood pressure and renal function. This medicine should not be administered to patients with severe hepatic impairment. (See section 2. Patients who should not receive this medicine under Precautions for Use.) ○ Elderly patients: Treatment is generally initiated at a low dose. When adjusting the dose, the patient's renal or cardiac function and coexisting diseases should be taken into consideration. Blood pressure should be monitored closely and more frequently in elderly patients.
Child dose
○ Children: The safety and efficacy of this medicine have not been established in pediatric patients under 18 years of age.

Ingredients

Manufacturer
Hanlim Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of essential hypertension not controlled with monotherapy

  • Essential hypertension
View approved original text

This medication is used for the treatment of patients with essential hypertension for whom blood pressure control is difficult even with monotherapy using Isamlodipine or Olmesartan Medoxomil. This drug effectively lowers blood pressure, reducing the burden on the heart and blood vessels. By continuously managing blood pressure, it reduces the risk of cardiovascular complications such as stroke and myocardial infarction. Appropriate dosage and administration will be guided based on the patient's condition, and continuous use is important. For safe treatment, regular blood pressure checks are recommended, and patients should follow their doctor's instructions. This drug helps improve hypertension.

How to take

Adult dose

This medicine should be taken once daily as 1 tablet with water, regardless of meals. If possible, it is recommended that it be taken at the same time each day (e.g., in the morning). Before starting this medicine, it is recommended that the dose be adjusted using the individual components (S-amlodipine (amlodipine) or olmesartan medoxomil). However, if blood pressure is not controlled with monotherapy using either individual component, switching directly to this medicine may be considered. The maximum dose of this medicine is 5/40 mg. The maximum blood pressure-lowering effect occurs within 2 weeks after administration; therefore, adjust the dose at intervals of at least 2 weeks, taking the patient's blood pressure response into consideration. The recommended doses are as follows. - 2.5/20 mg: For patients whose blood pressure is not adequately controlled with S-amlodipine 2.5 mg (amlodipine 5 mg) or olmesartan medoxomil 20 mg monotherapy. - 5/20 mg: For patients whose blood pressure is not adequately controlled with olmesartan medoxomil 20 mg monotherapy. - 2.5/40 mg: For patients whose blood pressure is not adequately controlled with 2.5/20 mg. - 5/40 mg: For patients whose blood pressure is not adequately controlled with 2.5/40 mg. ○ Patients with renal impairment: This medicine has not been studied in patients with renal impairment. However, the maximum dose of olmesartan medoxomil for patients with mild to moderate renal impairment (creatine clearance 20-60mL/min) is 20 mg once daily, and use of this medicine is not recommended in patients with moderate to severe renal impairment (e.g., creatinine clearance < 20 mL/min) or in patients on dialysis. Monitoring of potassium and creatinine levels is recommended in patients with moderate renal impairment. ○ Patients with reduced effective circulating blood volume: In patients who may have reduced effective circulating blood volume (Intravascular volume depletion) (e.g., patients receiving diuretics, especially those with renal impairment), it is recommended that treatment be initiated at a low dose with careful monitoring of their condition. ○ Patients with hepatic impairment: Use with caution in patients with mild to moderate hepatic impairment. The recommended initial dose of olmesartan medoxomil for patients with moderate hepatic impairment is 10 mg once daily, and the maximum dose is 20 mg once daily. Patients with hepatic impairment who are already receiving other antihypertensive agents and/or diuretics should be closely monitored for blood pressure and renal function. This medicine should not be administered to patients with severe hepatic impairment. (See section 2. Patients who should not receive this medicine under Precautions for Use.) ○ Elderly patients: Treatment is generally initiated at a low dose. When adjusting the dose, the patient's renal or cardiac function and coexisting diseases should be taken into consideration. Blood pressure should be monitored closely and more frequently in elderly patients.

Child dose

○ Children: The safety and efficacy of this medicine have not been established in pediatric patients under 18 years of age.

Precautions

This medication can cause serious harm to the fetus and newborn if taken during the second and third trimesters of pregnancy, so it must be discontinued immediately upon confirmation of pregnancy. This medication should not be taken by individuals who are allergic to any of the components or similar drugs, pregnant or nursing women, patients with severe liver disease or certain heart conditions, and those undergoing renal dialysis. Patients with fluid or sodium depletion may experience excessively low blood pressure when starting this medication, so their condition should be monitored closely. If blood pressure drops too low, appropriate treatment may be necessary. This drug has a vasodilatory effect and can cause acute hypotension or cardiac issues; therefore, patients with severe heart disease should be particularly cautious. Patients with reduced kidney function may experience further deterioration in renal function while taking this medication, necessitating regular monitoring. Patients with poor liver function should also use caution when taking this drug, and dosage adjustments may be needed. Side effects such as dizziness, headache, hypotension, edema, dyspepsia, skin rash, and others may occur, so any abnormal symptoms should be discussed with a physician. This drug can interact with other medications, particularly antihypertensives, diuretics, potassium supplements, certain antibiotics, and grapefruit juice, so caution is advised when taking them together. Women who are pregnant or planning to become pregnant should consider alternative treatments with established safety rather than this medication. Nursing mothers should be aware that this medication can pass into breast milk and may affect the infant, so they should cease breastfeeding or consult a doctor during treatment. This drug is not recommended for children under 18 years of age, as safety and efficacy have not been established. Elderly patients may have reduced liver, kidney, or heart function, so they should start at a lower dose and be monitored closely when taking this drug. Overdose of this medication can lead to severe hypotension and cardiac issues due to vascular dilation, so in case of overdose, immediate medical attention is required. This medication should be stored away from direct sunlight, humidity, and heat, and it is important to keep it out of reach of children.

Side effects

  • Drug hypersensitivity
  • hyperkalemia
  • decreased libido
  • dizziness
  • headache
  • orthostatic hypotension
  • drowsiness
  • paresthesia
  • sensory impairment
  • syncope
Show 65 more
  • vertigo
  • palpitations
  • rapid pulse
  • hypotension
  • orthostatic hypotension
  • dyspnea
  • cough
  • nausea
  • vomiting
  • indigestion
  • diarrhea
  • constipation
  • dry mouth
  • upper abdominal pain
  • rash
  • urticaria
  • muscle tension
  • limb pain
  • low back pain
  • frequent urination
  • erectile dysfunction
  • peripheral edema
  • swelling
  • dependent edema
  • fatigue
  • asthenia
  • facial edema
  • decreased serum potassium
  • increased serum creatinine
  • increased serum uric acid
  • increased gamma-glutamyl transferase
  • decreased hemoglobin and hematocrit
  • low back pain
  • bronchitis
  • increased creatine kinase
  • hematuria
  • hyperglycemia
  • hypertriglyceridemia
  • influenza-like symptoms
  • pharyngitis
  • rhinitis
  • sinusitis
  • asthenia
  • angioedema
  • chronic malabsorption syndrome
  • intestinal vascular edema
  • rhabdomyolysis
  • acute renal failure
  • hair loss
  • itching
  • autoimmune hepatitis
  • flushing
  • fatigue
  • abdominal pain
  • nausea
  • gynecomastia
  • jaundice
  • elevated liver enzymes
  • leukopenia
  • thrombocytopenia
  • toxic epidermal necrolysis
  • pronounced hypotension
  • excessive peripheral vasodilation
  • tachycardia
  • bradycardia

Not everyone experiences these, and they can vary from person to person.

Storage

This medication may be sensitive to air or moisture, so it should be stored in a sealed container. It is advisable to maintain a storage temperature between 1 and 30 degrees Celsius room temperature to preserve the drug's efficacy.

Appearance and packaging

Appearance

Reddish-brown round film-coated tablet

Package unit

30 tablets/bottle, 300 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.